EraCal Therapeutics AG Closes Seed Financing Round

EraCal Therapeutics AG, established as a spin-off from the University of Zurich and Harvard University, completes an oversubscribed seed financing round. Investors included Bernina BioInvest, Redalpine, the UZH Life Sciences Fund and private investors. The seed capital will be used to advance the preclinical development of Era-107, an appetite modulator that has a more specific effect than previous drugs and therefore causes fewer side effects. VISCHER acts as legal advisor to EraCal Therapeutics AG in the seed financing round. The VISCHER team includes Christian Wyss (Partner, Corporate / M&A), Luzius Zumstein (Associate, Corporate / M&A), Dr. Sara Ianni (Associate, Corporate / M&A), and Adrian Briner (Associate, Tax).

Press release

Christian Wyss

Attorney at Law

• Partner

• +41 58 211 33 39
• [email protected]

Luzius Zumstein

Attorney at Law

• Managing Associate

• +41 58 211 32 02
• [email protected]

Adrian Briner

Swiss Certified Public Accountant, Swiss Certified Tax Expert

• Counsel

• +41 58 211 32 18
• [email protected]